454 related articles for article (PubMed ID: 31361600)
21. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
22. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
Rotinen M; You S; Yang J; Coetzee SG; Reis-Sobreiro M; Huang WC; Huang F; Pan X; Yáñez A; Hazelett DJ; Chu CY; Steadman K; Morrissey CM; Nelson PS; Corey E; Chung LWK; Freedland SJ; Di Vizio D; Garraway IP; Murali R; Knudsen BS; Freeman MR
Nat Med; 2018 Dec; 24(12):1887-1898. PubMed ID: 30478421
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
24. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract][Full Text] [Related]
25. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
27. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
28. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
29. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
30. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
32. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
33. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
[TBL] [Abstract][Full Text] [Related]
34. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
35. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
Shao C; Yu B; Liu Y
Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
[TBL] [Abstract][Full Text] [Related]
37. CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.
Azur RAG; Olarte KCV; Ybañez WS; Ocampo AMM; Bagamasbad PD
PLoS One; 2024; 19(5):e0300413. PubMed ID: 38739593
[TBL] [Abstract][Full Text] [Related]
38. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
39. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
40. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
